Site search

Clear filter
2831 results for '' found
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 An
/
Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR-T cells in adult patients with multiple myeloma (NCT04318327)
Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR-T cells in adult patients with multiple myeloma (NCT04318327)
/
Catheter Ablation versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial (ACTRN12620000045910)
Catheter Ablation versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial (ACTRN12620000045910)
/
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor
/
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with R
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with R
/
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care
/
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (NCT03400332)
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (NCT03400332)
/
MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratum
MagnetisMM-5: An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of Elranatamab (Pf-06863135) Monotherapy And Elranatamab + Daratumumab Versus Daratum
/
An International Phase 2, Open-Label, One-Arm, Multi-Center Study to Evaluate Safety and Efficacy of PF-06835375 in Adult Participants with Moderate to Severe Primary Immune Thrombocytopenia (NCT
An International Phase 2, Open-Label, One-Arm, Multi-Center Study to Evaluate Safety and Efficacy of PF-06835375 in Adult Participants with Moderate to Severe Primary Immune Thrombocytopenia (NCT
/
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe
/
49 50 51 52 53